The therapy of kidney cancer with biomolecular drugs

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Di Lorenzo, G ^a   Buonerba, C ^a   Biglietto, M ^a   Scognamiglio, F ^a   Chiurazzi, B ^a   Riccardi, F ^a   Carteni G ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Metastatic renal cell cancer; Targeted therapies

Indexed keywords

ALPHA2A INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; FLUOROURACIL; INTERFERON; INTERLEUKIN 2; LEVOTHYROXINE; PAZOPANIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HISTOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; IMMUNOTHERAPY; KIDNEY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; INTERFERONS; KIDNEY NEOPLASMS; PROGNOSIS; PYRIDINES; PYRIMIDINES; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 78649727711     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70015-3     Document Type: Article

References (40)

1. Ravaud A, Wallerand H, Culine S, et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 2008, 54:315-325.
2. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol 2007, 51:1502-1510.
3. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor andplatelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9(1):327-337.
4. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
5. O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003, 9:5465-5476.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
8. Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009, 20:1535-1542.
9. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009, 6(4):219-228.
10. Ferrara N, Hillan KJ, Gerber HP, Novotny W Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
11. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
12. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-5428.
13. Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28:2144-2150.
14. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
15. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxiainducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002, 22:7004-7014.
16. Hara S, Oya M, Mizuno R Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 2005, 16:928-933.
17. Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo Park C Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol 2003, 84:166-172.
18. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
19. Sonpavde G, Hutson TE Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007, 9(2):115-119.
20. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010, 28:475-480.
21. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
22. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosinekinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
23. Sridhar SS, Hedley D, Siu LL Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005, 4:677-685.
24. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005, 23:965-972.
25. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
26. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
27. Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2007, 25(18S):5107.
28. Motzer R, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
29. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010 Jun 14, [Epub ahead of print].
30. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009, 7(6):618-630.
31. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Guidelines on Renal Cell Carcinoma. 2009, EAU guidelines (ISBN 978-90-79754-09-0), available to all members of the European Association of Urology at their website http://www.uroweb.org.
32. Sosman JA, Flaherty K, Atkins MB, et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J Clin Oncol 2006, 24:3031.
33. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1432-1439.
34. Escudier B How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma. J Clin Oncol 2010, 28:2125-2126.
35. Hainsworth JD, Spigel DR, Burris HA, Waterhouse D, Clark BL, Whorf R Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010, 28:2131-2136.
36. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
37. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008, 113:1552-1558.
38. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748.
39. Rini BI, Cohen DP, Lu D, et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Proceedings from 2010 ASCO Genitourinary Cancers Symposium, San Francisco, US, March 2010. Abstract n. 312.
40. Gore ME, Griffin CL, Hancock B, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010, 375:641-648.